RCAMU
ACHN

Rothschild & Co Asset Management US’s Achillion Pharmaceuticals ACHN Stock Holding History

Rothschild & Co Asset Management US’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-268,206
Closed -$3.29M – 355
2014
Q4 		$3.29M Buy
268,206
+5,573
+2% +$68.1K 0.07% 292
2014
Q3 		$2.62M Buy
+262,633
New +$2.44M 0.06% 312

Other funds holding ACHN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rothschild & Co Asset Management US's ACHN Position: Q1 2015 in Review

Rothschild & Co Asset Management US sold out of Achillion Pharmaceuticals (ACHN) in Q1 2015, closing a stake of 268,206 shares — an estimated $3.29M sold.

Rothschild & Co Asset Management US first reported a position in ACHN in Q3 2014 and held it in 2 quarters. The position peaked at $3.29M in Q4 2014. 173 funds tracked by Wall St. Rank hold ACHN as of Q1 2015.

  • Rothschild & Co Asset Management US reported no remaining Achillion Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Rothschild & Co Asset Management US sold 268,206 Achillion Pharmaceuticals shares in Q1 2015, an estimated $3.29M.
  • Rothschild & Co Asset Management US first reported a position in Achillion Pharmaceuticals in Q3 2014 and held it in 2 quarters.
  • Rothschild & Co Asset Management US's Achillion Pharmaceuticals position peaked at $3.29M in Q4 2014.
  • 173 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2015.

Based on Rothschild & Co Asset Management US's 13F filing for Q1 2015, filed 15 May 2015.